{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:26:54Z","timestamp":1787830014316,"version":"build-2784847793"},"reference-count":38,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","award":["516022524"],"award-info":[{"award-number":["516022524"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Treatment advancements in chronic myeloid leukaemia (CML) have made the disease manageable but carry significant risk of side effects. Bridging information gaps between patients and physicians through shared decision-making (SDM) is increasingly favoured, yet understanding treatment complexities remains a challenge. This study sought to identify decisional and informational needs of both patients and physicians in CML care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A qualitative study using semi-structured interviews was conducted to investigate the opinions, attitudes and preferences of both patients with chronic myeloid leukaemia and physicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Patients and physicians were recruited through the Dutch CMyLife platform, an initiative of haematologists, patients and patient organisations. They were provided with the participant information and invited to participate if interested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 15 interviews (n=10 patients, n=5 physicians) were conducted between April and October 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>A pre-defined interview guide was developed based on the Decisional Needs Assessment questionnaire. Interview transcripts were thematically analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight themes and 28 sub-themes were observed, highlighting patient needs, treatment choices and informational preferences. Patients emphasised the importance of understanding medication options and side effects, while physicians stressed the necessity of delivering up-to-date and comprehensible information. Almost all participants had experienced professionals making the treatment decision, without patient involvement, especially when initiating treatment. Some patients expressed too little information and missed partnership with professionals at treatment onset. Peer support, decision-making dynamics and the role of caregivers were also significant considerations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both shared and distinct perspectives on CML treatment decision-making between patients and physicians were revealed, underscoring the complexity of decisional needs in CML management. The findings emphasise the importance of patient-centred care, SDM and tailored communication strategies to optimise patient outcomes and satisfaction. Improved communication and evidence-based decision-making tools can significantly impact patient well-being. Further research and interventions are necessary to address the challenges in decision-making processes in CML care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-112705","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:10:42Z","timestamp":1769091042000},"page":"e112705","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Decisional needs among patients and physicians in the treatment of chronic myeloid leukaemia: a qualitative analysis in the Netherlands"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9848-2391","authenticated-orcid":false,"given":"Simone","family":"Mingels","sequence":"first","affiliation":[{"name":"Research Institute for Oncology and Reproduction GROW, Maastricht University, Maastricht, Netherlands"},{"name":"Department of Radiation Oncology MAASTRO, Maastricht University Medical Centre+, Maastricht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-7198","authenticated-orcid":false,"given":"Manon J J","family":"Cloots","sequence":"additional","affiliation":[{"name":"Institute for Nutrition and Translational Research in Metabolism NUTRIM, Maastricht University, Maastricht, Netherlands"},{"name":"Department of Gastroenterology and Hepatology, Maastricht Universitair Medisch Centrum+, Maastricht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolba","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboud universitair medisch centrum, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M A","family":"Blijlevens","sequence":"additional","affiliation":[{"name":"Department of Hematology, Radboud universitair medisch centrum, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard F M","family":"Posthuma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Reinier de Graaf Groep, Delft, Netherlands"},{"name":"Department of Hematology, Leiden University Medical Center, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre L A J","family":"Dekker","sequence":"additional","affiliation":[{"name":"Research Institute for Oncology and Reproduction GROW, Maastricht University, Maastricht, Netherlands"},{"name":"Department of Radiation Oncology MAASTRO, Maastricht University Medical Centre+, Maastricht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne R R","family":"Fijten","sequence":"additional","affiliation":[{"name":"Research Institute for Oncology and Reproduction GROW, Maastricht University, Maastricht, Netherlands"},{"name":"Department of Radiation Oncology MAASTRO, Maastricht University Medical Centre+, Maastricht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esri","family":"Wener","sequence":"additional","affiliation":[{"name":"CMyLife Program, A.T. TWINTEY, Eindhoven, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corien C G","family":"Kromkamp","sequence":"additional","affiliation":[{"name":"Department of Oncology, Rijnstate Hospital, Arnhem, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2026012206102964000_16.1.e112705.1","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010117","article-title":"Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future","volume":"10","author":"Minciacchi","year":"2021","journal-title":"Cells"},{"key":"2026012206102964000_16.1.e112705.2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2026012206102964000_16.1.e112705.3","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-010-0116-1"},{"key":"2026012206102964000_16.1.e112705.4","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31823dec8d"},{"key":"2026012206102964000_16.1.e112705.5","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/bjh.17989","article-title":"The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018","volume":"196","author":"Maas","year":"2022","journal-title":"Br J Haematol"},{"key":"2026012206102964000_16.1.e112705.6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.215"},{"key":"2026012206102964000_16.1.e112705.7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026012206102964000_16.1.e112705.8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11899-023-00703-w","article-title":"Real-world Management of CML: Outcomes and Treatment Patterns","volume":"18","author":"Held","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"2026012206102964000_16.1.e112705.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"2026012206102964000_16.1.e112705.10","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"2026012206102964000_16.1.e112705.11","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000969576.83189.62","article-title":"P668: CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING","volume":"7","author":"Lang","year":"2023","journal-title":"Hemasphere"},{"key":"2026012206102964000_16.1.e112705.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(99)00145-8"},{"key":"2026012206102964000_16.1.e112705.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2010.01219.x"},{"key":"2026012206102964000_16.1.e112705.14","doi-asserted-by":"publisher","DOI":"10.1037\/a0036834"},{"key":"2026012206102964000_16.1.e112705.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032921","article-title":"Knowing what the patient wants: a hospital ethnography studying physician culture in shared decision making in the Netherlands","volume":"10","author":"Spinnewijn","year":"2020","journal-title":"BMJ Open"},{"key":"2026012206102964000_16.1.e112705.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2011.02.004"},{"key":"2026012206102964000_16.1.e112705.17","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000000388"},{"key":"2026012206102964000_16.1.e112705.18","unstructured":"Jacobsen M , O\u2019Connor A , Stacey D . Decisional needs assessment in populations. 1999. Available: https:\/\/decisionaid.ohri.ca\/docs\/implement\/Population_Needs.pdf"},{"key":"2026012206102964000_16.1.e112705.19","unstructured":"CMyLife . Platform voor pati\u00ebnten met hematologische ziekten, betrokkenen en zorgverleners, Available: https:\/\/www.cmylife.nl"},{"key":"2026012206102964000_16.1.e112705.20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/14780887.2020.1769238","article-title":"One size fits all? What counts as quality practice in (reflexive) thematic analysis?","volume":"18","author":"Braun","year":"2021","journal-title":"Qual Res Psychol"},{"key":"2026012206102964000_16.1.e112705.21","unstructured":"NLQF NC . Referencing the dutch qualifications framework nlqf to the european qualifications framework: update september 2019 final version. 2019."},{"key":"2026012206102964000_16.1.e112705.22","unstructured":"Hematologie NVv . Richtlijn Chronische Myelo\u00efde Leukemie, 2023. Available: https:\/\/publicatie.hematologienederland.nl\/richtlijnen\/chronische-myeloide-leukemie-2"},{"key":"2026012206102964000_16.1.e112705.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.12.010"},{"key":"2026012206102964000_16.1.e112705.24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.093724"},{"key":"2026012206102964000_16.1.e112705.25","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1182\/bloodadvances.2020003044","article-title":"Decisional involvement and information preferences of patients with hematologic malignancies","volume":"4","author":"Loh","year":"2020","journal-title":"Blood Adv"},{"key":"2026012206102964000_16.1.e112705.26","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.348"},{"key":"2026012206102964000_16.1.e112705.27","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1188\/14.CJON.E12-E18","article-title":"Patient empowerment in the management of chronic myeloid leukemia","volume":"18","author":"Coleman","year":"2014","journal-title":"Clin J Oncol Nurs"},{"key":"2026012206102964000_16.1.e112705.28","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.3749","article-title":"Health information-seeking behavior of seniors who use the Internet: a survey","volume":"17","author":"Medlock","year":"2015","journal-title":"J Med Internet Res"},{"key":"2026012206102964000_16.1.e112705.29","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2217\/fon-2022-1267","article-title":"The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist","volume":"19","author":"Clements","year":"2023","journal-title":"Future Oncol"},{"key":"2026012206102964000_16.1.e112705.30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.pec.2021.06.025","article-title":"Filling the gaps of patient information needs and information perception in chronic myeloid leukemia with the patient-physician co-produced web-based platform CMyLife","volume":"105","author":"Ector","year":"2022","journal-title":"Patient Educ Couns"},{"key":"2026012206102964000_16.1.e112705.31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2013.03.008","article-title":"Supportive care needs of hematological cancer survivors: a critical review of the literature","volume":"88","author":"Hall","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026012206102964000_16.1.e112705.32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.2042-7174.2002.tb00602.x","article-title":"Is 15 per cent very common? Informing people about the risks of medication side effects","volume":"10","author":"Berry","year":"2011","journal-title":"Int J Pharm Pract"},{"key":"2026012206102964000_16.1.e112705.33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cam4.1915","article-title":"What information do patients want across their cancer journeys? A network analysis of cancer patients\u2019 information needs","volume":"8","author":"Tran","year":"2019","journal-title":"Cancer Med"},{"key":"2026012206102964000_16.1.e112705.34","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s11136-017-1611-8","article-title":"Recovering from chronic myeloid leukemia: the patients\u2019 perspective seen through the lens of narrative medicine","volume":"26","author":"Graffigna","year":"2017","journal-title":"Qual Life Res"},{"key":"2026012206102964000_16.1.e112705.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2322"},{"key":"2026012206102964000_16.1.e112705.36","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.96.5.219"},{"key":"2026012206102964000_16.1.e112705.37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/0284186X.2018.1512156","article-title":"Fear and forget: how anxiety impacts information recall in newly diagnosed cancer patients visiting a fast-track clinic","volume":"58","author":"Nguyen","year":"2019","journal-title":"Acta Oncol"},{"key":"2026012206102964000_16.1.e112705.38","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1037\/hea0000097","article-title":"Reducing patients\u2019 anxiety and uncertainty, and improving recall in bad news consultations","volume":"33","author":"van Osch","year":"2014","journal-title":"Health Psychol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-112705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:10:55Z","timestamp":1769091055000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-112705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjopen-2025-112705"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-112705","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}